LLY

1,044.51

-0.34%↓

JNJ

202.86

+0.41%↑

ABBV

229.52

-1.97%↓

UNH

311.09

+1.53%↑

AZN

88.99

-0.06%↓

LLY

1,044.51

-0.34%↓

JNJ

202.86

+0.41%↑

ABBV

229.52

-1.97%↓

UNH

311.09

+1.53%↑

AZN

88.99

-0.06%↓

LLY

1,044.51

-0.34%↓

JNJ

202.86

+0.41%↑

ABBV

229.52

-1.97%↓

UNH

311.09

+1.53%↑

AZN

88.99

-0.06%↓

LLY

1,044.51

-0.34%↓

JNJ

202.86

+0.41%↑

ABBV

229.52

-1.97%↓

UNH

311.09

+1.53%↑

AZN

88.99

-0.06%↓

LLY

1,044.51

-0.34%↓

JNJ

202.86

+0.41%↑

ABBV

229.52

-1.97%↓

UNH

311.09

+1.53%↑

AZN

88.99

-0.06%↓

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Open

4.28 3.13

Buy Sell

Overview

Share price change

24h

Current

Min

4.08

Max

4.34

Key metrics
By Trading Economics
Income	5.5M -28M
Sales	8.2M 13M
EPS	-0.47
Profit margin	-208.694
Employees	172
EBITDA	8.7M -27M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+217.06% upside

Market Stats
By TradingEconomics
Market Cap	-26M 229M
Previous open	1.15
Previous close	4.28

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 lis 2025, 23:36 UTC

Hot Stocks

Stocks to Watch: Nvidia, Kulicke & Soffa, Regeneron

19 lis 2025, 22:13 UTC

Earnings

Acquisitions, Mergers, Takeovers

Palo Alto Networks to Buy Chronosphere for $3.35 Billion, Posts Higher 1Q Revenue -- Update

19 lis 2025, 21:55 UTC

Major Market Movers

Amgen Lung Cancer Drug Gets Full Approval From FDA

19 lis 2025, 21:43 UTC

Acquisitions, Mergers, Takeovers

Palo Alto Networks to Buy Chronosphere for $3.35 Billion

19 lis 2025, 23:55 UTC

Market Talk

Gold Rises on Possible Investment Demand -- Market Talk

19 lis 2025, 23:54 UTC

Market Talk

BHP Vicuna JV Offers Significant Copper Output, At a Cost -- Market Talk

19 lis 2025, 23:47 UTC

Earnings

Lenovo Group 2Q EPS $2.52 >0992.HK

19 lis 2025, 23:46 UTC

Earnings

Lenovo Group: Delivered Double-Digit Yr-on-Yr Rev Growth Across All Main Business Groups and Sales Geographies >0992.HK

19 lis 2025, 23:45 UTC

Earnings

Lenovo Group 2Q Rev $20.5B >0992.HK

19 lis 2025, 23:42 UTC

Market Talk

Nikkei May Rise After Nvidia's Strong Earnings Soothe Investors' Nerves -- Market Talk

19 lis 2025, 23:42 UTC

Market Talk

Global Equities Roundup: Market Talk

19 lis 2025, 23:41 UTC

Earnings

Lenovo Group 2Q Adj Net $512.0M Vs. $409.0M >0992.HK

19 lis 2025, 23:41 UTC

Earnings

Lenovo Group 2Q Net $340.0M Vs. Net $359.0M >0992.HK

19 lis 2025, 23:40 UTC

Earnings

Lenovo Group 2Q Rev $20.45B Vs. $17.85B >0992.HK

19 lis 2025, 22:55 UTC

Earnings

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 4th Update

19 lis 2025, 22:41 UTC

Earnings

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 3rd Update

19 lis 2025, 22:30 UTC

Acquisitions, Mergers, Takeovers

CICC Seeks Trading Halt in Hong Kong, Shanghai Stock Exchange

19 lis 2025, 22:30 UTC

Earnings

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 2nd Update

19 lis 2025, 22:30 UTC

Acquisitions, Mergers, Takeovers

CICC Plans to Acquire Brokerage Firms via Share-Swap Agreement

19 lis 2025, 22:27 UTC

Acquisitions, Mergers, Takeovers

China International Capital Plans to Acquire Brokerage Firms Cinda Securities, Dongxing Securities

19 lis 2025, 22:08 UTC

Earnings

ZTO Express (Cayman) 3Q Rev $1.67B >ZTO

19 lis 2025, 22:00 UTC

Earnings

Investors Cheer Blockbuster Nvidia Earnings -- WSJ

19 lis 2025, 21:58 UTC

Earnings

Acquisitions, Mergers, Takeovers

Palo Alto Networks to Buy Chronosphere for $3.35B, Posts Higher 1Q Rev -- Update

19 lis 2025, 21:52 UTC

Earnings

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- Update

19 lis 2025, 21:50 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

19 lis 2025, 21:49 UTC

Market Talk

Earnings

Nvidia Quiets Investor Fears With Ballooning Demand -- Market Talk

19 lis 2025, 21:38 UTC

Earnings

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- WSJ

19 lis 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

Palo Alto Networks to Buy Chronosphere for $3.35B

19 lis 2025, 21:27 UTC

Acquisitions, Mergers, Takeovers

Exact Sciences Stock Jumps on Reported Deal Interest from Abbott Laboratories -- Barrons.com

19 lis 2025, 21:24 UTC

Earnings

Acquisitions, Mergers, Takeovers

Palo Alto Networks 1Q Next-Generation Security ARR $5.9 B >PANW

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

217.06% upside

12 Months Forecast

Average 13.57 USD 217.06%

High 25 USD

Low 8 USD

Based on 9 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.